KARINA ROLDAN: Open Payments
NPI 1619222742 · CARMICHAEL, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,389 in 102 payments from 24 companies in 2025. Trend: 2023 $2,615 · 2024 $2,692 · 2025 $2,389
Food & beverage: $2,389
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $509 |
| Aimmune Therapeutics, Inc. | 11 | $428 |
| Novo Nordisk Inc | 8 | $275 |
| Neurocrine BioSciences, Inc. | 7 | $240 |
| GlaxoSmithKline, LLC. | 9 | $181 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $104 |
| Ardelyx, Inc. | 3 | $78 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $65 |
| AstraZeneca Pharmaceuticals LP | 1 | $64 |
| Amgen Inc. | 3 | $57 |
Products named: ZENPEP, LINZESS, INGREZZA, Ozempic, TRELEGY ELLIPTA, CREON, JARDIANCE, IBSRELA.
Industry payments across CA — which companies pay providers there.
